Cognito Therapeutics and Ochsner Health have established a Brain Health Collaboratory aimed at enhancing care models for cognitive decline and Alzheimer’s disease in the Gulf South. This initiative integrates Cognito’s investigational Spectris platform with Ochsner’s extensive clinical network, creating the region’s first statewide platform for non-invasive brain health innovation. The collaboration aims to develop a Brain Health Index to monitor cognitive health, disease progression, and treatment responses in diverse populations, including those eligible for both Medicare and Medicaid.

This partnership is significant as it seeks to expand access to innovative cognitive health solutions across urban and rural areas, addressing a critical gap in Alzheimer’s care. The integration of Spectris—a non-invasive device designed to stimulate gamma-frequency brain activity—could offer new therapeutic avenues, especially given its FDA Breakthrough Device designation and ongoing evaluation in the HOPE Trial.

For longevity professionals, this initiative underscores the potential for real-world applications of neuroprotective technologies and the importance of developing comprehensive data on clinical outcomes and cost-effectiveness in cognitive health interventions.

Source: longevity.technology